See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Trade War
Stock Markets
Social Media
Donald Trump
Natural Disasters
Artificial Intelligence
US Economy
Recession
Trade
European Union
Published • loading... • Updated

Newswise Latest News: news and press releases in science, medicine, life, and business

Summary by Newswise
For patients with inadequately controlled type 2 diabetes, switching to tirzepatide improves glucose control and increases weight loss more so than maximizing dulaglutide dose.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All
Left
Center
Right
NewswiseNewswise

Newswise Latest News: news and press releases in science, medicine, life, and business

For patients with inadequately controlled type 2 diabetes, switching to tirzepatide improves glucose control and increases weight loss more so than maximizing dulaglutide dose.

·Charlottesville, United States
Read Full Article
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

Switching to Tirzepatide Outweighs Upping Dulaglutide Dose

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals, we need to decide whether to increase a current […] The post Switching to Tirzepatide Outweighs Upping Dulaglutide Dose fi…

Read Full Article
researchsquare.comresearchsquare.com

Effect of tirzepatide on OSA-related cardiometabolic risk measures in SURMOUNT-OSA

Background: Obstructive sleep apnea (OSA) is associated with obesity and cardiovascular risk. Results from the SURMOUNT-OSA studies demonstrated significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment wi...

Read Full Article
European Medical JournalEuropean Medical Journal

Investigating FDA Reports of Tirzepatide-Thyroid Cancer Connection

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this means for clinical practice.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

European Medical Journal broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Obesity

Obesity

Science

Science

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal